Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193154
Status:
COMPLETED
Last Update Posted:
2014-04-01
First Post:
2005-09-12
Brief Title:
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase II Trial of Tarceva OSI-774 and Avastin Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this phase II trial we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a strong biologic rationale based on Cancer Biology VHLHIFVEGFEGFr
Detailed Description:
Upon determination of eligibility all patients will receive
Tarceva Avastin
Tarceva Avastin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AVF2488s | None | None | None |